To assess whether pIC, CpG, CpG/pIC, PD-L1 Ab, 41BB Ab, CpG/pIC/PD-L1-Ab and Combo (CpG/pIC/PD-L1/41BB Abs) are capable of enhancing OVA-specific CD8+ T cell responses and inhibiting 3LLOVA tumor growth, we subjected our 3LLOVA lung cancer model to these various treatment regimens (Figure 2A). Here, CD8A is linked to lung cancer.